Navigation Links
Research practices must be changed to minimize fraud, deception
Date:3/22/2011

Ann Arbor, Mich. In 1998, a study linking the measles, mumps and rubella (MMR) vaccine to autism in children appeared in a respected medical journal. For a decade, the study grabbed headlines worldwide. Worried parents rejected the life-saving vaccine for their children and those with autistic children agonized that they allowed an injection that caused the condition.

But the vaccine-autism research was a fraud. The paper was retracted 12 years later, denounced as an elaborate deception.

"The fraud in that MMR study epitomizes how fabricated research can lead to a domino effect of tragic consequences," says Vineet Chopra, M.D., F.A.C.P., F.H.M., assistant professor of Internal Medicine at U-M. "Patients fear potentially lifesaving interventions, clinicians alter practice and scientists and governments waste precious resources to evaluate researchers' claims."

Chopra expresses these concerns in a commentary published in the Journal of the American Medical Association March 23 with Matthew Davis, M.D., M.A.P.P., associate professor of pediatrics and communicable diseases, internal medicine and public policy at the University of Michigan Medical School and Gerald R. Ford School of Public Policy. They call for changes throughout the research process to adjust expectations for researchers that conduct studies, the journals that publish results and the public that responds to the findings.

Chopra and Davis emphasize the critical importance of equipoisea state of genuine uncertainty on the part of the researcher as to what a study will reveal.

"In an era of increasing competition for funding and publication, researchers face mounting pressure to report the results they wish to see," says Davis. "Of course, it's natural for the public to want unequivocal advances in understanding and the latest accomplishments in medical research. But research doesn't always yield those results.

"The key is for funders, journals, the media and the public to value equipoise in the research process, rather than only the results."

In their JAMA commentary, Chopra and Davis recommend steps to reach research equipoise:

  1. Mandate the public release of all available data in connection with a study, as opposed to specific data associated with outcomes.
  2. Reduce publication bias, in which medical journals accept and publish chiefly those studies with statistically significant results. This jeopardizes consideration and dissemination of research pertaining to findings on both sides of an issue, and influences investigators before research begins.
  3. Shift the focus of public and private sponsors of research from outcome to process, affirming that study veracity is more valuable than results.
  4. Train researchers to recognize, appreciate and root out biases in their work.

"Researchers may lie about their research for personal or political gain. They make front page news when they get caught, but they represent a small part of the overall picture. A broader problem occurs when a researcher conducts a study with an answer to their question already in mind. Their certainty, rather than genuine uncertainty, influences their investigation and reporting, leading to results that may not be accurate," says Chopra.


'/>"/>

Contact: Mary F. Masson
mfmasson@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Gift will allow Mayo researchers to explore cause of dementia in the elderly
2. Philanthropic pledge triples funds for TGen ovarian cancer research
3. Stanford researchers discover molecular determinant of cell identity
4. Terminolgy matters in parents willingness to enroll their children in research
5. CDC, Cook County and Rush collaborate to research and prevent hospital infections
6. Researchers discover possible biomarker and therapeutic target for melanoma
7. Innovative technique gives vision researchers insight into how people recognize faces
8. Important funding for nanomedicine research to improve diagnosis and treatment
9. Treatment for alcohol dependence might work best in certain populations, research suggests
10. HIV research included in journal
11. Fragile X researcher honored by March of Dimes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: